INSERM U955, eq15 Translational Psychiatry team, Paris Est University, DHU Pe-PSY, Pôle de Psychiatrie et d'addictologie des Hôpitaux Universitaires H Mondor, Créteil, France.
EA 3279 Research Unit - Public Health: Chronic Diseases and Quality of Life, Aix-Marseille University, Marseille, France.
Acta Psychiatr Scand. 2016 Dec;134(6):469-484. doi: 10.1111/acps.12656. Epub 2016 Oct 15.
It is unknown whether a cytokine signature may help the identification of subgroup of patient who would respond to personalized treatment. As interleukin-1 beta (Il-1β) seems to play a major role in mood disorder, a systematic review and meta-analysis of its potential role in major depressive disorder (MDD) was carried out.
A systematic search was performed to identify appropriate MDD vs. control studies pertaining to Il-1β. Methodological quality and possible moderators were also assessed.
A total of 1922 studies were identified, and 53 articles were selected. Results showed an association between increased blood IL-1β and MDD in high-quality studies only. No association with age was found. No IL-1β gene-related polymorphisms has been associated with MDD. No effect of antidepressant on IL-1β level has been found, although the antidepressants investigated were various. Qualitative analyses indicate that MDD coupled to a history of childhood trauma may be a subgroup for IL-1β -targeted therapies. No difference in studies utilizing a stimulation method has been identified to date.
The present work has confirmed IL-1β as a biological marker of interest for innovative MDD treatments. However, further studies are needed to clarify the patients with MDD who may benefit from these therapies.
目前尚不清楚细胞因子特征是否有助于确定对个体化治疗有反应的患者亚群。由于白细胞介素-1β（IL-1β）似乎在心境障碍中发挥着重要作用，因此对其在重度抑郁症（MDD）中的潜在作用进行了系统评价和荟萃分析。
进行了系统检索，以确定与 IL-1β 相关的适当 MDD 与对照研究。还评估了方法学质量和可能的调节因素。
共确定了 1922 项研究，最终选择了 53 篇文章。结果表明，仅在高质量研究中发现血液 IL-1β 升高与 MDD 之间存在关联。未发现与年龄有关。尚未发现与 MDD 相关的 IL-1β 基因相关多态性。尽管研究中使用的抗抑郁药种类繁多，但未发现抗抑郁药对 IL-1β 水平有影响。定性分析表明，MDD 伴发儿童期创伤史可能是针对 IL-1β 的靶向治疗的亚组。迄今为止，尚未发现使用刺激方法的研究存在差异。
本研究证实了 IL-1β 作为创新 MDD 治疗的生物标志物具有重要意义。但是，需要进一步的研究来阐明可能从这些治疗中受益的 MDD 患者。
